A New Trial For Patients Expressing NY-ESO-1 in California


It's a phase 1b trial and it's a different approach than the trial at NIH. In particular, there is no restriction on HLA type:



There's been many immunotherapy trials with disappointing results so far but researchers are learning more each step of the way. Let's keep optimistic!